Zevra Therapeutics to Participate at Upcoming Investor Conferences
29 Agosto 2024 - 6:30AM
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company),
a rare disease therapeutics company, today announced that Neil F.
McFarlane, President and Chief Executive Office of Zevra, will
present at upcoming investor conferences during the month of
September 2024. Additionally, management will be available for
one-on-one meetings with registered attendees at each conference.
- H.C. Wainwright 26th Annual Global
Investment Conference in New York, NY, on Monday, September 9,
2024, at 2:00 p.m. ET.
- Cantor Annual Healthcare Conference
in New York, NY, on Tuesday, September 17, 2024, at 2:30 p.m.
ET.
The live webcasts will be accessible via the
“Events & Presentations” section of Zevra’s website at
investors.zevra.com.
About Zevra:
Zevra Therapeutics is a rare disease company
combining science, data, and patient needs to create
transformational therapies for diseases with limited or no
treatment options. Our mission is to bring life-changing
therapeutics to people living with rare diseases. With unique,
data-driven development and commercialization strategies, the
Company is overcoming complex drug development challenges to make
new therapies available to the rare disease community.
For more information, please visit www.zevra.com
or follow us on X (formerly Twitter) and LinkedIn.
Caution Concerning Forward-Looking
Statements:
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include all
statements that do not relate solely to historical or current
facts, including without limitation statements regarding upcoming
events or Zevra’s participation at such events. Forward-looking
statements are based on information currently available to Zevra
and its current plans or expectations. They are subject to several
known and unknown uncertainties, risks, and other important factors
that may cause our actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. These and other important factors are described in
detail in the "Risk Factors" section of Zevra’s Annual Report on
Form 10-K for the year ended December 31, 2023, Zevra’s Quarterly
Report for the quarter ended June 30, 2024, and Zevra’s other
filings with the Securities and Exchange Commission. While we may
elect to update such forward-looking statements at some point in
the future, except as required by law, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
Although we believe the expectations reflected in such
forward-looking statements are reasonable, we cannot assure that
such expectations will prove correct. These forward-looking
statements should not be relied upon as representing our views as
of any date after the date of this press release.
Contacts:
Nichol Ochsner +1 (732)
754-2545 nochsner@zevra.com
Russo Partners Contacts:
Adanna G. Alexander, Ph.D.+1 (646)
942-5603adanna.alexander@russopartnersllc.com
Ignacio Guerrero-Ros, Ph.D. +1 (646) 942-5604
ignacio.guerrero-ros@russopartnersllc.com
Zevra Therapeutics (NASDAQ:ZVRA)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Zevra Therapeutics (NASDAQ:ZVRA)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024